Cercar
13/05/2025
Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases
Ortiz, MA, Anguera, G, Cantó, E, Alejandre, J, Mora, J, Osuna-Gómez, R, Mulet, M, Mora, P, Antonijuan, A, Sánchez, S, Ramírez, O, Orantes, V, Maroto, P, Vidal, S. Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(10)DOI:10.3390/ijms26104669. PMID:40429810. IF:4.900(Q1/3D).
01/05/2025
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. Jto Clinical And Research Reports. 2025; 6(5)DOI:10.1016/j.jtocrr.2025.100815. PMID:40248457. IF:(Q/D).
18/04/2025
The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis
Zuellig, JA, Adam, R, Udry, F, Tibau, A, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis. Cancers. 2025; 17(8)DOI:10.3390/cancers17081359. PMID:40282533. IF:4.400(Q2/3D).
01/04/2025
Will I feel better? Raising the bar for quality of life in oncology
Tibau, A, Romano, A, Kesselheim, AS. Will I feel better? Raising the bar for quality of life in oncology. Nature Reviews Clinical Oncology. 2025; 22(4)DOI:10.1038/s41571-025-01002-4. PMID:40021787. IF:82.200(Q1/1D).
01/04/2025
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
Del Muro, XG, López-Bravo, DP, Cuéllar-Rivas, MA, Maroto, P, Giannatempo, P, Castellano, D, Climent, MA, Valderrama, BP, de Liaño, AG, López-Montero, L, Mina, L, Alcalá-López, D, Sampayo-Cordero, M, Necchi, A. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. European Urology Oncology. 2025; 8(2)DOI:10.1016/j.euo.2024.04.021. PMID:38749903. IF:9.300(Q1/1D).
01/04/2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
Soo, RA, Vervita, K, Früh, M, Cho, B, Majem, M, Abreu, DR, Ribi, K, Callejo, A, Moran, T, Gomez, MD, Provencio, M, Addeo, A, Han, JY, Granados, ALO, Reck, M, Blasco, A, Campelo, RG, González, MAS, Britschgi, C, Roschitzki-Voser, H, Ruepp, B, Gasca-Ruchti, A, Haberecker, M, Dafni, U, Peters, S, Stahel, RA. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. LUNG CANCER. 2025; 202DOI:10.1016/j.lungcan.2025.108454. PMID:40023017. IF:4.400(Q1/2D).